Special Issue

The Challenges and Prospects in Diagnostics of Otolaryngology

Message from the Guest Editor

The purpose of this Special Issue is to offer readers and colleagues several new diagnostic tools in the otorhinolaryngologic fields and beyond. For instance, with the perspective of precision medicine and a multidisciplinary approach, this Special Issue aims to describe not only the new challenges in otorhinolaryngological diagnostics but also to provide useful tools in clinical practice to personalize therapeutic strategies with a view to patient customization. Furthermore, the need for an integrated multidisciplinary approach in the evaluation of pathologies in the rhinological, otological, and laryngological fields cannot be overlooked. These are the reasons why I proposed this Special Issue of the Journal of Personalized Medicine, to collect papers about "The Challenges and Prospects in Diagnostics of Otolaryngology" in all of the fields of otorhinolaryngology as well as in related fields. Studies should describe challenges and prospects in the diagnostics of otorhinolaryngology using basic-science-, clinical-, and population-based approaches.

Guest Editor

Dr. Elena Cantone

Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples "Federico II", 80131 Naples, Italy

Deadline for manuscript submissions

closed (5 February 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/132547

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

